导管消融作为阵发性心房颤动一线治疗:系统评价与荟萃分析
该系统评价与荟萃分析纳入6项随机对照试验,比较导管消融与抗心律失常药物作为症状性阵发性心房颤动一线治疗的疗效与安全性。结果显示导管消融显著降低心房心律失常复发风险(RR 0.64,95%CI 0.51-0.80,p<0.01)及医疗资源使用,严重不良事件风险无统计学差异。
要点
- 导管消融较抗心律失常药物显著降低心房心律失常复发风险达36%。
- 导管消融组严重不良事件风险与药物组无统计学差异(RR 0.87)。
- 导管消融显著减少症状性心律失常复发和医疗资源使用。
核心结论
- 对于症状性阵发性心房颤动患者,导管消融作为一线治疗优于抗心律失常药物,显著减少任何心房心律失常和症状性心房心律失常的复发以及医疗资源使用,且安全性相当。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Cochrane Library和Embase于2000年1月1日至2021年3月19日发表的随机对照试验。
- 共纳入6项研究,导管消融组609例,抗心律失常药物组603例。
主要发现
- 导管消融组212/609例出现心房心律失常复发,药物组318/603例,相对风险降低36%(RR 0.64,95%CI 0.51-0.80,p<0.01)。
- 严重不良事件风险两组无统计学差异(RR 0.87,95%CI 0.58-1.30,p=0.49;导管消融组107/609 vs 药物组126/603)。
- 症状性心房心律失常复发在导管消融组显著更低(109/505 vs 186/504;RR 0.53,95%CI 0.35-0.79)。
- 医疗资源使用在导管消融组显著更低(126/397 vs 185/394;RR 0.65,95%CI 0.48-0.89)。
- 随访期间交叉率在导管消融组较药物组降低79%(RR 0.21,95%CI 0.13-0.32,p<0.01)。
临床怎么用
- 对于症状性阵发性心房颤动患者,可考虑将导管消融作为一线治疗选择,以降低心律失常复发和医疗资源使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy and safety of catheter ablation (CA) compared with antiarrhythmic drugs (AADs) as first-line treatment for symptomatic paroxysmal atrial fibrillation (AF). METHODS: Systematic review and meta-analysis of randomised controlled trials identified using MEDLINE, Cochrane Library and Embase published between 01/01/2000 and 19/03/2021. The primary efficacy endpoint was the first documented recurrence of atrial arrhythmias following the blanking period. The primary safety endpoint was a composite of all serious adverse events (SAEs). RESULTS: From 441 records, 6 studies met the inclusion criteria. 609 patients received CA, while 603 received AAD therapy. 212/609 patients in the CA group had a recurrence of atrial arrhythmias as compared with 318/603 in the AADs group resulting in a 36% relative risk reduction (risk ratio: 0.64, 95% CI 0.51 to 0.80, p<0.01). The risk of all SAEs was not statistically different between CA and AAD (0.87, 0.58 to 1.30, p=0.49); 107/609 SAE in the CA group vs 126/603 in the AAD group. Both recurrence of symptomatic atrial arrhythmias (109/505 vs 186/504) and healthcare utilisation (126/397 vs 185/394) were significantly lower in the CA group (0.53, 0.35 to 0.79 and 0.65, 0.48 to 0.89, respectively). There was a 79% reduction in the crossover rate during follow-up among patients randomised to CA compared with AAD (0.21, 0.13 to 0.32, p<0.01). CONCLUSIONS: First-line treatment with CA is superior to AAD therapy in patients with symptomatic paroxysmal AF, as it significantly reduces the recurrence of any atrial arrhythmias and symptomatic atrial arrhythmias, and healthcare resource utilisation with comparable safety profile.
引用
- Imberti JF, Ding WY, Kotalczyk A, et al. Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis. Heart. 2021. PMID: 34261737. doi:10.1136/heartjnl-2021-319496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。